226 199

Cited 4 times in

When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response

Authors
 Wonseok Kang  ;  Jun Yong Park 
Citation
 WORLD JOURNAL OF GASTROENTEROLOGY, Vol.20(23) : 7207-7212, 2014 
Journal Title
 WORLD JOURNAL OF GASTROENTEROLOGY 
ISSN
 1007-9327 
Issue Date
2014
MeSH
Antiviral Agents/administration & dosage* ; Biomarkers/blood ; Drug Administration Schedule ; Hepatitis B virus/drug effects* ; Hepatitis B virus/growth & development ; Hepatitis B, Chronic ; Humans ; Nucleosides/administration & dosage* ; Nucleotides/administration & dosage* ; Remission Induction ; Time Factors ; Treatment Outcome ; Viral Load
Keywords
Antiviral therapy ; Cessation ; Chronic hepatitis B ; Durability ; Nucleos(t)ide analogue
Abstract
Introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). Although current international guidelines for the management of CHB provide information regarding when to begin the antiviral therapy with NAs, there is no clear consensus on when to stop the treatment, especially for those who respond to the therapy. Hepatitis B surface antigen loss has been regarded as an ideal endpoint of oral antiviral therapy with NAs, however since this is rarely achieved, practical endpoints have been suggested by the international guidelines. Despite the stopping rules recommended by the international guidelines, whether oral antiviral therapy with NAs can be safely discontinued is of major concern. While attention has been drawn to whether antiviral treatment with NAs can be a finite therapy, there is lack of sufficient data on off-treatment durability of highly potent NAs. Based on the available evidences, current guidelines for stopping NA therapy seems to be inadequate in terms of off-treatment durability, with relapse rates of more than 40% for both hepatitis Be antigen (HBeAg)-positive and HBeAg-negative patients. Therefore, further studies are required to accumulate data on off-treatment durability of highly potent NAs, and future studies are warranted to identify adequate predictive markers that could provide supplementary information to guide the timing of stopping NA therapy.
Files in This Item:
T201403516.pdf Download
DOI
10.3748/wjg.v20.i23.7207
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Won Suk(강원석)
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/99977
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse